{"prompt": "['Product: MK-3475', '85', 'Protocol/Amendment No.: 604-09', 'Table 9', 'Clinical Laboratory Tests', 'Hematology', 'Hematocrit, hemoglobin, platelet count, WBC (total and', 'differential), RBC, absolute lymphocyte count, absolute', 'neutrophil count', 'Chemistry', 'Albumin, alkaline phosphatase, alanine aminotransferase,', 'aspartate aminotransferase, bicarbonate (only required if done as', 'part of standard of care by local laboratory), calcium, chloride,', 'creatinine, glucose, phosphorus, potassium, sodium, total', 'bilirubin, direct bilirubin (if total bilirubin >ULN), total protein,', 'blood urea nitrogen or urea (one or the other should be collected', 'per institutional standard; both of these laboratory tests are not', 'required), LDHa', 'Thyroid Function Tests', 'Total T3 or free T3 (T3 is preferred; if not available, free T3 may', 'be tested), FT4, and TSH', 'Coagulation Parameters', 'PT/INR', 'Hepatitis Serologiesb', 'HbsAg, HCV RNA (qualitative), Anti-HCV', 'Pregnancy test', 'If the urine test is not negative, then a serum test must be', 'performed.', 'Urinalysis', 'Blood, glucose, protein, specific gravity', 'Microscopic exam should be performed if abnormal results are', 'noted', 'Abbreviations: FT4=free thyroxine; HbsAg=hepatitis B surface antigen; HCV=hepatitis C virus; LDH=Lactate', 'dehydrogenase; PT=prothrombin time; RBC=red blood cells; T3=triiodothyronine; TSH=thyroid-stimulating', 'hormone; ULN=upper limit of normal; WBC=white blood cells.', 'a', 'If the local laboratory is unable to perform these tests, the site should submit the sample to the central', 'laboratory for testing. Details are provided in the Laboratory Manual.', 'b Hepatitis C antibody testing is allowed in countries where HCV RNA is not part of standard of care. Testing', 'for Hepatitis B and Hepatitis C should be performed as mandated by the local health authority.', 'For both the Initial Treatment Phase and the Second Course Phase:', 'Screening laboratory tests should be performed within 10 days prior to the first dose', 'of trial treatment, with the exception of the hepatitis serologies which may be', 'performed within 28 days of the first dose of trial treatment in the Initial Treatment', 'Phase only. Testing for hepatitis B and hepatitis C should be performed as mandated', 'by the local health authority.', 'Clinical laboratory tests must be conducted within 72 hours prior to first dose of trial', 'treatment in each cycle, with the exception of laboratory tests performed by the', 'central lab, which may be conducted up to 10 days prior to first dose of trial', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '86', 'Protocol/Amendment No.: 604-09', 'treatment. Laboratory test results must be reviewed by the investigator or qualified', 'designee and found to be acceptable prior to administration of first trial treatment.', 'For laboratory tests performed by the central laboratory, any results not available', 'prior to dosing must be reviewed by the investigator or qualified designee within', '48 hours of receipt and found to be acceptable prior to subsequent administration of', 'trial treatment.', 'During the Initial Treatment Phase, laboratory tests will also be performed at the', 'Day 8 Visit of each cycle. Results must be reviewed by the investigator or qualified', 'designee within 48 hours of receipt.', 'Unresolved abnormal laboratory test results that are drug-related AEs should be', 'followed until resolution.', 'Laboratory tests do not need to be repeated after the end of treatment if laboratory test results', 'are within the normal range.', '7.1.3.2 harmacokinetic/Pharmacodynamic Evaluations', 'Pembrolizumab', 'The accumulation of robust PK and anti-drug antibodies (ADA) data has allowed for the', 'adequate characterization of the clinical pharmacology of pembrolizumab across indications.', 'Therefore, upon approval of Amendment 07, each site is to stop the collection of PK and', 'ADA samples for all subjects. Blood samples for PK and ADA collected prior to', 'Amendment 07 may be stored. Analysis will be performed only if required.', 'Exploratory drug-drug interaction analysis', 'The accumulation of robust PK data has allowed for adequate characterization of the', 'potential for drug-drug interactions between pembrolizumab and chemotherapy. Therefore,', 'upon approval of protocol amendment 06, each site is to stop the collection of PK samples', 'for etoposide only. Blood samples for etoposide PK collected prior to protocol', 'amendment 06 may be stored. Analysis will be performed only if required.', 'Patient-reported Outcomes', 'For PROs, the EQ-5D-5L, EORTC QLQ-C30, and EORTC QLQ-LC13 questionnaires will', 'be administered by trained study site personnel and completed electronically by the subjects', 'themselves.', 'It is strongly recommended that electronic PROs are administered prior to drug', 'administration, AE evaluation, and disease status notification. The electronic PROs are', 'completed in the following order: EQ-5D-5L first, then EORTC QLQ-C30, and lastly, the', 'EORTC QLQ-LC13 at the time points specified in the Trial Flow Charts and briefly', 'summarized below.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}